Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker

Affiliations

¹ From the Rocky Mountain Multiple Sclerosis Clinic (J.F.F.), Salt Lake City, UT; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center at Dallas; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas.
² From the Rocky Mountain Multiple Sclerosis Clinic (J.F.F.), Salt Lake City, UT; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center at Dallas; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas. olaf.stuve@utsouthwestern.edu.

Editorial

John F Foley et al. Neurol Neuroimmunol Neuroinflamm. 2020.

. 2020 Mar 10;7(3):e706.

doi: 10.1212/NXI.0000000000000706. Print 2020 May.

¹ From the Rocky Mountain Multiple Sclerosis Clinic (J.F.F.), Salt Lake City, UT; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center at Dallas; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas.
² From the Rocky Mountain Multiple Sclerosis Clinic (J.F.F.), Salt Lake City, UT; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center at Dallas; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas. olaf.stuve@utsouthwestern.edu.

No abstract available

Comment on

Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.
Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S. Bringeland GH, et al. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 4;7(3):e678. doi: 10.1212/NXI.0000000000000678. Print 2020 May 4. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32019768 Free PMC article.

1. Shirani A, Stuve O. Natalizumab: perspectives from the bench to bedside. Cold Spring Harb Perspect Med 2018;8:a029066. - PMC - PubMed
1. Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 2019;31:65–71. - PubMed
1. van Kempen ZLE, Doesburg D, Dekker I, et al. . The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms. Neurology 2019;93:e1579–e1586. - PubMed
1. Bringeland G, Blaser N, Myhr KM, Vedeler CA, Gavasso S. Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy. Neurol Neuroimmunol Neuroinflamm 2020;7:e678 10.1212/NXI.0000000000000678. - DOI - PMC - PubMed
1. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183–187. - PubMed